Digest Network Come funziona
Network
/
Società
Sy
Non verificato

Synnovation Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati
14/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Eventi
Fiere
Industria
Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310
Fonte
Synnovation Therapeutics
Emittente
Business Wire
1.00
0
08/05/2025
Mercato del lavoro
Farmaceutica
Salute
Medicina - Varie
Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors
Fonte
Synnovation Therapeutics
Emittente
Business Wire
1.00
0
24/02/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors
Fonte
Synnovation Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0